Pfizer Inc said that final results from the late-stage trial of its Covid-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency US authorisation within days.
The drugmaker said efficacy of the vaccine developed with German partner BioNTech was consistent across age and ethnicity demographics.
It also said there were no major side effects, a sign that the immunisation could be employed broadly around the world. Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94%.
The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective. Moderna on Monday released preliminary data for its